CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 274 enrolled
Drug / intervention
Test varnish +1 moredrug
Likely dose
Test varnish 0.2 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04947527
NCT04947527Phase 2Completed

Phase 2 Efficacy & Safety Evaluation of Advantage Anti-Caries Varnish for Primary Prevention

Advantage Silver Dental Arrest, LLC·interventional·Posted Jul 1, 2021·Updated Oct 9, 2025

In Brief

A Phase 2 clinical trial evaluating Test varnish and Placebo for Dental Caries in Children. Completed, enrolled 274 participants across 1 site.

Detailed Summary

The purpose of the study is to determine the efficacy \& safety of Advantage Anti-Caries Varnish for primary prevention. The objectives are: 1\) To determine if Advantage Anti-Caries Varnish (test varnish) is superior to an active control varnish (5% Sodium Fluoride, no Povidone-Iodine) in the prevention of caries lesions in the primary dentition. Specifically, prevention of caries lesions in primary teeth that either are sound, have only d1 (white spots) lesions or unerupted at baseline; and 2) To document the safety of the test varnish.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States Minor Outlying Islands
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedJul 1, 2021
Enrollment StartJun 4, 2022
Primary CompletionJun 19, 2024
Study CompletionAug 5, 2024
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 5.0 years ago

Interventions

Test varnishdrug

A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.

Placebodrug

A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.